497 A Study of ALPN-202, a PD-L1-dependent CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in patients with advanced malignancies

Abstract

BackgroundDespite successes with checkpoint inhibition (CPI) in a wide range of tumors, most patients demonstrate primary or acquired resistance, thus driving the need for better IO therapy. Research has suggested...